Apalutamide: all 85 studies that test it
Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingNCT07783282Phase 1
- Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PETRecruitingNCT06758882Phase 2
- PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.RecruitingNCT06274047Phase 3
- Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE TrialRecruitingNCT06067269Phase 2
- Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)Not yet recruitingNCT05778097Phase 2
- Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone MetastasesRecruitingNCT05740488Not applicable
- Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT TreatmentNot yet recruitingNCT05717582Phase 2
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingNCT05406999Phase 2
- TherApeutics in Early ProState Cancer (TAPS02)RecruitingNCT05191680Phase 2
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
- An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate CancerRecruitingNCT04997252Not applicable
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingNCT04812366Phase 2
- Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in JapanRecruitingNCT04601441Phase 4
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingNCT03903835Phase 3
- Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPRecruitingNCT03899077Phase 2
- Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyTerminatedNCT05960578Phase 2Results posted
- Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate GlandCompletedNCT04530552Phase 2Results posted
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland CarcinomaActive, not recruitingNCT04325828Phase 2Results posted
- A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)CompletedNCT04108208Phase 4Results posted
- Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADTTerminatedNCT03777982Phase 3Results posted
- Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate CancerCompletedNCT03503344Phase 2Results posted
- Apalutamide in Treating Patients With Prostate Cancer Before Radical ProstatectomyActive, not recruitingNCT03412396Phase 2Results posted
- Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE TrialActive, not recruitingNCT03371719Phase 2Results posted
- A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)CompletedNCT03311555Phase 2Results posted
- Systemic and Tumor-Directed Therapy for Oligometastatic Prostate CancerCompletedNCT03298087Phase 2Results posted
- Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate CancerCompletedNCT03279250Phase 2Results posted
- Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate CancerCompletedNCT03098836Phase 2Results posted
- A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate CancerTerminatedNCT03093272Phase 2Results posted
- A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerCompletedNCT03009981Phase 3Results posted
- Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing ProstatectomyCompletedNCT02903368Phase 2Results posted
- A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomyCompletedNCT02849990Phase 2Results posted
- AASUR in High Risk Prostate CancerCompletedNCT02772588Phase 2Results posted
- Apalutamide and Leuprolide in Intermediate and High-risk Prostate CancerCompletedNCT02770391Phase 2Results posted
- Apalutamide in Treating Patients With Prostate Cancer Who Are in Active SurveillanceTerminatedNCT02721979Phase 2Results posted
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPCActive, not recruitingNCT02489318Phase 3Results posted
- An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Active, not recruitingNCT02257736Phase 3Results posted
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT01946204Phase 3Results posted
- The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate CancerCompletedNCT01790126Phase 2Results posted
- Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)CompletedNCT01171898Phase 1/2Results posted
- A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCActive, not recruitingNCT05884398Phase 3
- Androgen Receptor Signaling and Prostate-Specific Membrane Antigen ExpressionActive, not recruitingNCT05683964Early Phase 1
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerActive, not recruitingNCT05367440Phase 1/2
- Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerStatus unknownNCT05212857Phase 2
- Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerCompletedNCT04666129Phase 1
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate CancerActive, not recruitingNCT04557059Phase 3
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialActive, not recruitingNCT04513717Phase 3
- Oral EPI-7386 in Patients with Castration-Resistant Prostate CancerTerminatedNCT04421222Phase 1
- Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate CancerTerminatedNCT04409288Phase 3
- Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical ProstatectomyActive, not recruitingNCT04295447Phase 2
- Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate CancerActive, not recruitingNCT04267887Phase 2
- Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyActive, not recruitingNCT04181203Phase 3
- A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic FunctionCompletedNCT04154774Phase 1
- Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE TrialActive, not recruitingNCT04134260Phase 3
- Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerActive, not recruitingNCT03902951Phase 2
- Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate CancerActive, not recruitingNCT03821792Phase 2
- A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy ParticipantsCompletedNCT03802682Phase 1
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyActive, not recruitingNCT03767244Phase 3
- A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT03523442Phase 1
- Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate CancerWithdrawnNCT03488810Phase 3
- Therapeutics in Active Prostate Cancer SurveillanceCompletedNCT03365297Phase 2
- Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate CancerTerminatedNCT03360721Phase 2
- Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC PatientsWithdrawnNCT03173859Phase 2
- Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)Status unknownNCT03141671Phase 2
- Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate CancerCompletedNCT03124433Phase 2
- Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate CancerCompletedNCT03088124Phase 2
- Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical ProstatectomyActive, not recruitingNCT03080116Phase 2
- Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing SurgeryActive, not recruitingNCT02949284Phase 2
- A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)CompletedNCT02924766Phase 1
- Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPCCompletedNCT02913196Phase 1
- A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate CancerWithdrawnNCT02906605Phase 2
- Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone LevelsCompletedNCT02867020Phase 2
- Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese ParticipantsCompletedNCT02835508Phase 1
- Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate CancerWithdrawnNCT02811809Phase 2
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02703623Phase 2
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate CancerActive, not recruitingNCT02592317Phase 1
- A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc StudyCompletedNCT02578797Phase 1
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASActive, not recruitingNCT02531516Phase 3
- A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic FunctionCompletedNCT02524717Phase 1
- Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927CompletedNCT02230033Phase 1
- A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT02162836Phase 1
- Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male ParticipantsCompletedNCT02160756Phase 1
- A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02123758Phase 1
- A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male ParticipantsCompletedNCT02031666Phase 1
- 14C-ARN-509 Microtracer Label AME and Absolute BA StudyCompletedNCT01822041Phase 1
- Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetateCompletedNCT01792687Phase 1